QIAGEN N.V. today announced a broad agreement with Ares Genetics, a subsidiary of Curetis N.V. CURE, -0.10% to develop innovative bioinformatics and assay solutions to accelerate research targeting the growing global health challenges posed by antibiotic-resistant bacteria.
{iframe}https://www.marketwatch.com/press-release/qiagen-partners-with-ares-genetics-to-advance-global-fight-against-antibiotic-resistant-pathogens-2019-02-18{/iframe}